home / stock / hook / hook short
Short Information | HOOKIPA Pharma Inc. (NYSE:HOOK)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 92,211 |
Total Actual Volume | 1,787,892 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 4,611 |
Average Short Percentage | 5.03% |
Is there a HOOK Short Squeeze or Breakout about to happen?
See the HOOK Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-12-2020 | $12.50 | $12.04 | $12.6839 | $12.00 | 80,315 | 4,147 | 5.16% |
02-11-2020 | $12.71 | $12.49 | $12.8159 | $12.40 | 44,392 | 660 | 1.49% |
02-10-2020 | $13.09 | $12.72 | $13.33 | $12.70 | 35,152 | 3,093 | 8.8% |
02-07-2020 | $12.57 | $13.13 | $13.30 | $12.57 | 52,249 | 6,928 | 13.26% |
02-06-2020 | $13.73 | $12.56 | $14.14 | $12.50 | 65,671 | 3,226 | 4.91% |
02-05-2020 | $13.06 | $13.69 | $13.95 | $12.9221 | 54,415 | 1,794 | 3.3% |
02-04-2020 | $12.79 | $12.95 | $13.02 | $12.61 | 44,264 | 2,662 | 6.01% |
02-03-2020 | $12.16 | $12.59 | $12.99 | $12.01 | 51,188 | 3,270 | 6.39% |
01-31-2020 | $12.66 | $12.00 | $12.98 | $11.99 | 106,856 | 1,766 | 1.65% |
01-30-2020 | $12.83 | $12.66 | $13.4431 | $12.55 | 38,672 | 3,213 | 8.31% |
01-29-2020 | $12.41 | $12.75 | $13.2858 | $12.41 | 68,435 | 3,611 | 5.28% |
01-28-2020 | $13.15 | $12.41 | $13.9802 | $12.26 | 70,814 | 4,235 | 5.98% |
01-27-2020 | $12.21 | $13.00 | $13.82 | $12.17 | 141,310 | 11,429 | 8.09% |
01-24-2020 | $14.01 | $12.06 | $14.3662 | $12.005 | 140,232 | 8,191 | 5.84% |
01-23-2020 | $12.23 | $13.80 | $14.00 | $12.05 | 222,240 | 17,682 | 7.96% |
01-22-2020 | $12.14 | $12.05 | $12.4967 | $11.91 | 123,646 | 2,561 | 2.07% |
01-21-2020 | $12.40 | $12.20 | $12.60 | $11.83 | 320,214 | 12,805 | 4% |
01-17-2020 | $11.35 | $11.19 | $11.37 | $11.08 | 31,104 | 77 | 0.25% |
01-16-2020 | $11.2896 | $11.25 | $11.58 | $11.07 | 49,334 | 852 | 1.73% |
01-15-2020 | $11.48 | $11.16 | $11.635 | $11.015 | 47,389 | 9 | 0.02% |
News, Short Squeeze, Breakout and More Instantly...
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2 data with additional patients in Q2 2024; Company will also provide pivotal trial design and ...
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...